Basic Informations
C.V
Dr. Wafaa Rabee Mohamed Mohamed
Master Title
Pharmacological study of the possible interactions between certain antidiabetic and antianxiety drugs in experimentally-induced diabetic animals
Master Abstract
Diabetes mellitus (DM) is a group of metabolic disorders characterized by chronic hyperglycemia resulting from relative or absolute insulin deficiency with or without insulin resistance. As anxiolytics may have influence on glycemic control in diabetics, the present study was conducted to investigate the possible influence of diazepam and buspirone in streptozotocin-induced DM and their possible interactions with rosiglitazone or glimepiride. Diabetes was induced by streptozotpcin (50 mg/kg i.p.). Rats were classified into 10 groups namely: normal control, diabetic control, rosiglitazone (10 mg/kg p.o.), glimepiride (10 mg/kg), diazepam (5 mg/kg) buspirone (20 mg/kg i.p.) or combination of diazepam or buspirone with rosiglitazone or glimepiride. All test drugs were given as single as well as repeated dose for one and two weeks. Diazepam significantly improved the effect of rosiglitazone or glimepiride on the levels of serum glucose, insulin, C-peptide, liver glycogen content and on oxidative stress biomarkers including serum lipid peroxides, blood glutathione levels and blood superoxide dismutase activity of diabetic rats. In conclusion, diazepam increased the antidiabetic and the antioxidant actions of rosiglitazone or glimepiride which may be of considerable value in the treatment of diabetes mellitus. There was no significant interaction between rosiglitazone or glimepiride and buspirone on the measured parameters, so, buspirone can be safely administered as an anxiolytic in diabetic patients treated with rosiglitazone.
PHD Title
Pharmacological Study on the Possible Protective Effects of Certain Antioxidants against Cisplatin-Induced Hepatotoxicity and Nephrotoxicity.
PHD Abstract
In the present study, the effects of three antioxidants namely hesperidin, thymoquinone and quercitrin on several parameters related to cisplatin-induced nephrotoxicity and hepatotoxicity in rats were studied in comparison with silymarin. The antioxidant drugs were given for normal as well as cisplatin-treated rats. Drugs were given for 7 days starting one day before cisplatin injection. The effects of the test drugs were estimated on serum creatinine and BUN levels, serum ALT and AST activities and serum TG and TC levels. Furthermore, the effect of test drugs was studied on kidney and liver contents of MDA, GSH and NO. Histopathological examination of both kidney and liver tissues was done. In addition, western blot analysis was done to determine the effect of cisplatin and test drugs on NF-??B and phosphorylated Akt expression levels in kidney and liver tissues. In addition, an in vitro experiment was done to detect the effect of test drugs on the anticancer activity of cisplatin when combined with it on two different cell lines namely human breast adenocarcinoma (MCF-7 and human hepatocellular carcinoma (HepG-2) using MTT assay. Results showed that test drugs significantly reduced cisplatin-induced elevations in serum Cr, BUN levels, ALT and AST activities, TG and total cholesterol levels. They also reduced cispaltin-induced oxidative stress by significant reduction in kidney and liver MDA and NO content and elevation of GSH content. In addition, test drugs significantly reduced cisplatin-induced increased NF-??B expression and decreased p-Akt expression in both kidney and liver. The histopathological examination revealed that test drugs greatly protected kidney and liver against cisplatin-induced injury. Hesperidin, thymoquinone & quercitrin could be promising agents for clinical use as nephro and hepato protection against cisplatin-induced nephrotoxicity and hepatotoxicity. Their effects were similar to that of silymarin.